TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01324505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Semaglutide will be administered once weekly by s.c. (under the skin) injections in the abdomen. A total of 13 doses of semaglutide will be administered according to a predefined dosing scheme

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo semaglutide will be administered once for securing eligibility of subjects (willingness and ability to self inject) at the screening visit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microgyn®
Description: Microgyn® will be given as once daily oral dosing in two periods, each of 8 days' duration. One tablet contains levonorgestrel 0.15 mg and ethinylestradiol 0.03 mg.
Study: NCT01624389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F18-AV45
Description: This study will recruit a total of 200 evaluable subjects (50 cognitively normal volunteers, 100 MCI, and 50 AD, respectively) Each evaluable subject involved in this study must fulfill all the inclusion and exclusion criteria according the subject grouping.~Safety measurement will be evaluated by medical history, vital signs, physical examinations, laboratory examinations and collecting of adverse events.
Study: NCT01612936

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bronchoscopy, Segmental Allergen Challenge and Broncheoalveolar Lavage
Description: On the day of the first bronchoscopy,BAL will first be performed in the lingula without instillation of diluent or allergen.Then, a 2-ml aliquot of isotonic diluent is instilled into the right upper lobe. Then, the procedure will be repeated in the right middle lobe with instillation of 2-ml of standardized cat or mite allergen solution.A test dose concentration of allergen is administered first consisting of 2 ml of allergen at 1/10th(Cat,D.farinae) or 1/30th(D. pteronyssinus) the threshold concentration.If on visual inspection through the bronchoscope, there is no evidence of mucosal inflammation after two minutes, a second segmental allergen challenge will be done in the right middle lobe using 2-ml of full-dose allergen at the threshold concentration(Cat,D.farinae) or 1/3th the threshold concentration(D.pteronyssinus).This dose will be predetermined by quantitative skin prick testing.A second bronchoscopy is performed 24 hours after delivery of allergen extract and diluent.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET-CT imaging(13NN perfusion/ventilation, 18FDG inflammation, and CT imaging)
Description: Imaging is first performed the evening prior to the 1st bronchoscopy.An IV catheter is placed.An attenuation correction is performed to remove image distortion using a chest CT volumetric scan.Subjects are instructed to exhale to the same mean lung volume of the CT scan and hold their breath for 20sec.Simultaneous with apnea,13NNsaline is injected IV and a series of PET scans is acquired.Then subjects resume breathing, matching their previous respiratory rate and tidal volume.After 3 min,within an interval of 1 min,spirometry and 2 deep inhalations are performed,followed by 1 min of washout. For the second imaging visit, which will occur 24 hour later, the imaging sequence will be repeated as described above, but will also include 18FDG infusion.At least 30 minutes after the 13NN injection,10mCi of 18FDG is infused. Then, images are collected over a 75 minutes.Venous blood is sampled at 5 different time points over a 40-45 minute time window to determine plasma radioactive levels.
Study: NCT03658655

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem Cells From Human Exfoliated Teeth
Description: Basic treatment:~The original treatment regimen will be maintained during the study period, insulin dose could be adjusted with the change of blood glucose, while the type and dose of oral hypoglycemic drugs remained unchanged (except when side effects of drugs or insulin preparations were stopped, but patients still had frequent hypoglycemia).~Stem cell therapy:~Usage: drip slowly, 50ml normal saline first, then Stem Cells From Human Exfoliated Teeth (during 60 min), then 50ml normal saline.
Study: NCT04419584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modified Qing-Ying Decoction
Description: Herbal granules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Identical looking placebo
Description: Placebo granules
Study: NCT02648178

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HALO
Description: HALO manufactures e-cigarettes which will be distributed to patients. Two products, the G6 and tank model will be used.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HALO
Description: HALO manufactures e-cigarettes which will be distributed to patients. Two products, the G6 and tank model will be used.
Study: NCT01414283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PSMA ADC
Description: PSMA ADC administered IV
Study: NCT04873791

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of geriatric individuals living in home environment and nursing home.
Description: Assessments explained in the arm section were made as described in one session in both group

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of geriatric individuals living in home environment and nursing home.
Description: Assessments explained in the arm section were made as described in one session in both group
Study: NCT05149651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Totalfill
Description: Totalfill® Bioceramic Root Repair Material -Fast Set Putty is a pre-mixed, bioactive calcium silicate cement which used as pulpotomy agent to treat extensive decayed tooth indicated for pulpotomy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTA
Description: ProRoot White MTA® is a bioactive calcium silicate cement which used as pulpotomy agent to treat extensive decayed tooth indicated for pulpotomy.
Study: NCT03135158

Intervention type: OTHER
Intervention: Exposure to vaginal delivery
Description: Women who have vaginal births are observed for a minimum of 1 hour postpartum
Study: NCT01841125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: escitalopram
Description: escitalopram 15mg, QD(once a day), Oral medication, 24weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo 15mg, QD(once a day), Oral medication
Study: NCT01745744

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells from adipose tissue
Description: - Infusion of mesenchymal stem cells from adipose tissue administered intraarterially: 0.5x106 cells / kg of patient weight and 1x106 cells / kg of patient weight.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells from adipose tissue
Description: - Infusion of mesenchymal stem cells from adipose tissue administered intraarterially: 0.5x106 cells / kg of patient weight and 1x106 cells / kg of patient weight.
Study: NCT01726400

Intervention type: DRUG
Intervention: Pegylated interferon alpha
Description: Subcutaneous weekly pegylated interferon alpha and daily oral ribavirin treatment as per standard treatment. The dosages for interferon and ribavirin are as per therapeutic guidelines and are based on weight, genotype and previous treatments.

Intervention type: DRUG
Intervention: Ribavirin
Description: Subcutaneous weekly pegylated interferon alpha and daily oral ribavirin treatment as per standard treatment. The dosages for interferon and ribavirin are as per therapeutic guidelines and are based on weight, genotype and previous treatments.
Study: NCT03494530

Intervention type: DRUG
Group type: OTHER
Intervention: Edoxaban 60 MG
Description: Anticoagulant used to treat atrial fibrillation

Intervention type: DRUG
Group type: OTHER
Intervention: Edoxaban 60 MG
Description: Anticoagulant used to treat atrial fibrillation

Intervention type: DRUG
Group type: OTHER
Intervention: Edoxaban 30 mg
Description: Anticoagulant used to treat atrial fibrillation

Intervention type: DRUG
Group type: OTHER
Intervention: Edoxaban 30 mg
Description: Anticoagulant used to treat atrial fibrillation
Study: NCT00178919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-NMMA
Description: IV infusion of 125, 250 and 500 mcg/Kg/min for 15 minutes each dose. The main outcome is the maximal increase in blood pressure produced at the end of the infusions or a maximal systolic blood pressure of 160 mm Hg. It could be achieved after the first dose or the third.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-NMMA
Description: IV infusion of 125, 250 and 500 mcg/Kg/min for 15 minutes each dose. The main outcome is the maximal increase in blood pressure produced at the end of the infusions or a maximal systolic blood pressure of 160 mm Hg. It could be achieved after the first dose or the third.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethaphan
Description: IV infusion for the duration of the study at 4-6 mg/min depending on autonomic blockade. This is only to produce transient pharmacological blockade of the autonomic nervous system in order to allow the full expression of the inhibition of nitric oxide synthase. There is no direct outcome associated with this intervention.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethaphan
Description: IV infusion for the duration of the study at 4-6 mg/min depending on autonomic blockade. This is only to produce transient pharmacological blockade of the autonomic nervous system in order to allow the full expression of the inhibition of nitric oxide synthase. There is no direct outcome associated with this intervention.
Study: NCT00823433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral penicillin V
Description: 2 grams of oral penicillin V given within 4 hours of delivery.
Study: NCT03541967

Intervention type: DEVICE
Group type: OTHER
Intervention: ADHEAR and PONTO 3 SUPER POWER on softband hearing aids
Description: Device: ADHEAR non-implantable bone conduction hearing aid Comparator: PONTO 3 SUPER POWER bone conduction hearing aid with softband

Intervention type: DEVICE
Group type: OTHER
Intervention: ADHEAR and PONTO 3 SUPER POWER on softband hearing aids
Description: Device: ADHEAR non-implantable bone conduction hearing aid Comparator: PONTO 3 SUPER POWER bone conduction hearing aid with softband
Study: NCT03267719

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laser therapy
Description: Transvaginal erbium-laser treatment
Study: NCT02398422

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Listening Project Protocol
Description: The filtered-music intervention will consist of listening to computer-altered acoustic stimulation, designed to modulate the frequency band of vocal music passed to the participant. The frequency characteristics of the acoustic stimulation are selected to emphasize the relative importance of specific frequencies in conveying the information embedded in human speech. Modulation of the acoustic energy within the frequencies of human voice, similar to an exaggerated vocal prosody, are hypothesized to recruit and modulate the neural regulation of the middle ear muscles and to functionally reduce sound hypersensitivities and improve auditory processing.~The non-filtered music intervention will consist of the same music as the filtered-music intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Listening Project Protocol
Description: The filtered-music intervention will consist of listening to computer-altered acoustic stimulation, designed to modulate the frequency band of vocal music passed to the participant. The frequency characteristics of the acoustic stimulation are selected to emphasize the relative importance of specific frequencies in conveying the information embedded in human speech. Modulation of the acoustic energy within the frequencies of human voice, similar to an exaggerated vocal prosody, are hypothesized to recruit and modulate the neural regulation of the middle ear muscles and to functionally reduce sound hypersensitivities and improve auditory processing.~The non-filtered music intervention will consist of the same music as the filtered-music intervention.
Study: NCT04214067

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Brachytherapy
Description: Undergo vaginal brachytherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Description: Undergo vaginal brachytherapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: External Beam Radiation Therapy
Description: Undergo EBRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo EBRT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT01697553

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: home automation pack coupled to teleassistance service

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home without automation pack coupled to teleassistance service
Study: NCT01689727

Intervention type: DRUG
Group type: OTHER
Intervention: Technetium Tc 99m EC20
Study: NCT01756079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: boceprevir

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PegIFN-2b

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Study: NCT00351884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin AM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vildagliptin pm

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT02143076

Intervention type: BEHAVIORAL
Intervention: Demographic Questionnaire
Description: At study enrollment, participants will complete a questionnaire to collect demographic information about the participant's family background, education and living situation.

Intervention type: BEHAVIORAL
Intervention: Medical Adherence Measure Questionnaire
Description: At the two-month follow-up visit, participants will be asked to complete a questionnaire describing all medications prescribed for them, when they take their medications, how much medication they take each time, how many times during the week they missed taking or were late taking each medication, reasons why they missed or were late, and how they manage their medications.~In the case that a participant's clinic schedule is delayed greater than two months from the time of consent (e.g., missed appointment, change in clinic appointment frequency), procedures scheduled for the anticipated 2-month visit will take place at the participant's next clinic appointment.

Intervention type: BEHAVIORAL
Intervention: Acceptability Questionnaire
Description: At the two-month follow-up visit, participants will be asked to complete a questionnaire about their perceptions of using the Wise electronic medication container.~In the case that a participant's clinic schedule is delayed greater than two months from the time of consent (e.g., missed appointment, change in clinic appointment frequency), procedures scheduled for the anticipated 2-month visit will take place at the participant's next clinic appointment.
Study: NCT03325946

Intervention type: BEHAVIORAL
Intervention: ACQUIRE Therapy
Description: Intensive therapy services combined with operant conditioning during treatment delivered by trained OT or PTs

Intervention type: BEHAVIORAL
Intervention: ACQUIRE Therapy
Description: Intensive therapy services combined with operant conditioning during treatment delivered by trained OT or PTs

Intervention type: BEHAVIORAL
Intervention: ACQUIRE Therapy
Description: Intensive therapy services combined with operant conditioning during treatment delivered by trained OT or PTs

Intervention type: BEHAVIORAL
Intervention: ACQUIRE Therapy
Description: Intensive therapy services combined with operant conditioning during treatment delivered by trained OT or PTs
Study: NCT02307682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brolucizumab ophthalmic solution
Description: Ophthalmic solution for IVT injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brolucizumab ophthalmic solution
Description: Ophthalmic solution for IVT injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept ophthalmic solution
Description: Ophthalmic solution for IVT injection
Study: NCT04214067

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT04214067

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03301870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATx201 Gel 4%
Description: 4% active gel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATx201 Gel 4%
Description: 4% active gel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Positive Control
Description: Sodium Lauryl Sulfate 0.05% (w/v), USP in sterile, distilled Water for Injection, USP
Study: NCT04214067

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: X-Ray Imaging
Description: Undergo x-rays

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo x-rays
Study: NCT01553214

Intervention type: DRUG
Group type: OTHER
Intervention: Filgrastim
Description: Donors shall receive G-CSF 480 mcg as a single 1.6-mL subcutaneous injection 12 to 24 hours prior to donation.

Intervention type: DRUG
Group type: OTHER
Intervention: Dexamethasone
Description: Donors shall ingest dexamethasone 8 mg (two 4-mg tablets) orally 12 hours prior to donation.
Study: NCT02752685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Paclitaxel
Study: NCT04638647

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Secukinumab s.c. injection
Description: Secukinumab pre-filled syringes (PFS) for s.c. injection
Study: NCT03948971

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Venogram
Description: The 5 French (5F) diagnostic catheter will be navigated into the inferior then superior vena cava and then into the internal jugular bulb on the dominant venous side (as determined from the arteriographic images). Next, a 0.027 inch microcatheter will be navigated using fluoroscopic guidance into the superior sagittal sinus and a venogram will then performed by injecting a small dose of contrast. Next, the venous sinus pressure waveforms will be recorded as the catheter is withdrawn into the jugular bulb and then in the superior vena cava to obtain a central venous pressure. Once completed, the catheters will be removed and the sheaths will be removed. Manual pressure will be held at the venous access site for a few minutes. The arterial sheath will be closed based upon standard arteriogram protocol.
Study: NCT00445211

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: Heparin administered at 500units/hour while on Intra-Aortic balloon Pump (IABP).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Without Heparin
Description: Intra-Aortic balloon Pump (IABP) without Heparin.
Study: NCT02997436

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser speckle flowmetry
Description: A galvanic current (0.1 mA) will be applied between 2 patches on the forearm of patient and protocol was repeated at 4 minutes.~Microvascular response to current application (CIV) will be recorded by laser speckle flowmetry 10 minutes later.~Measurement of the value of skin blood flow (by laser speckle) at the stimulated area as compare to a non stimulated adjacent skin value taken as a reference Usual treatment will be recorded
Study: NCT01426373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deoxycholic acid injection
Description: Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.
Study: NCT04219553

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Antimicrobial stewardship
Description: The multifaceted AMS intervention includes pharmacist education, a clinical decision support tool, a parent/guardian questionnaire, and individualized monthly audit and feedback with each pharmacist.
Study: NCT03579316

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adavosertib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adavosertib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceralasertib
Description: Given PO